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Abstract Gas6 is a ligand for an Axl/Sky receptor tyrosine 
kinase subfamily and has a structure composed of a Gla domain, 
four EGF-like domains and a C-terminal sex hormone-binding 
globulin (SHBG)-like domain. When examining the role of each 
domain in receptor-binding and biological activities of Gas6, we 
found that receptor-binding and mitogenic activities were 
markedly reduced by inhibiting γ-carboxylation of the Gla 
domain, while a Gas6 mutant composed of only an SHBG-like 
domain retained both of these activities. Thus, the SHBG-like 
domain is apparently an entity indispensable for Gas6 activities, 
and γ-carboxylation of the Gla domain has a regulatory role in 
retaining the activity of native Gas6. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The protein encoded by growth arrest-specific gene 6 (Gas6) 
was initially identified as a gene product inducibly expressed 
in fibroblasts in response to serum starvation [1]. Recent stud-
ies from our laboratory and others have demonstrated that 
Gas6 is a ligand for Axl, Sky and Mer receptor tyrosine kin-
ases [2-5], with the Gas6 binding affinities in the order of 
Axl > Sky > Mer [5]. These receptors are typified by the cell 
adhesion molecule-related extracellular ligand-binding domain 
composed of two immunoglobulin-like motifs and two fibro-
nectin type III motifs [6-10]. Gas6 was recently found to act 
as a growth-potentiating factor for thrombin-induced prolif-
eration of vascular smooth muscle cells [11]. Gas6 also pre-
vented serum starvation-induced cell death of these cells [12]. 
Mitogenic and survival activities of Gas6 for serum-starved 
fibroblasts and Schwann cells have also been described [13,14]. 
Gas6 has a structure similar to that of protein S, a vitamin 
K-dependent plasma protein with anticoagulant activity, with 
43% amino acid identity [1,15]. Similar to protein S, Gas6 is 
composed of several defined structural domains; an N-termi-
nal γ-carboxyglutamic acid (Gla) domain, followed by a short 
loop domain, four tandem repeats of epidermal growth factor 
(EGF)-like domains and a C-terminal sex hormone-binding 
""Corresponding author. Fax: (81) 92-642-2645. 
E-mail: kmizuscb@mbox.nc.kyushu-u.ac.jp 
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globulin (SHBG)-like domain [1]. The Gla domain, which is 
present in various proteins involved in blood coagulation, is 
generated by vitamin K-dependent γ-carboxylation of a clus-
ter of Glu residues and is thought to be involved in intra-
molecular and intermolecular protein-protein or protein-
membrane interactions through Ca2+-binding [16,17], The C-
terminal domains of protein S and Gas6 have a sequence 
similarity with human SHBG and rat androgen-binding pro-
tein, and these sequences are also distantly related to base-
ment membrane proteins, such as laminin and merosin [18]. 
Based on the characteristic domain structure of Gas6 com-
pared with other known ligands for receptor tyrosine kinases, 
it is interesting to know which domain of Gas6 is essential for 
its receptor-binding and biological activities and if γ-carbox-
ylation in the Gla domain is involved in these activities. In 
this respect, Mark et al. recently reported data showing the 
importance of the C-terminal SHBG-like domain for receptor-
binding and receptor-stimulating activities of Gas6 [19], but 
the biological activity of this domain has not been shown. The 
role of γ-carboxylation in the Gla domain also remains un-
known. We report here that the SHBG-like domain has full 
mitogenic activity on fibroblasts and γ-carboxylation of the N-
terminal Gla domain significantly contributes to bring out the 
activity of native Gas6. 
2. Materials and methods 
2.1. Plasmid construction 
Gas6 mutants used in this study are schematically shown in Fig. 
2A. The 2.8-kb Gas6 cDNA [11] was isolated from a rat brain cDNA 
library, and subcloned into pBluescript SK1I~ (Stratagene) or 
pGEM7 (Promega) at EcoRl site to generate pBS-Gas6 or pGEM-
Gas6. To construct pGEM-AG, a 280-bp EcoRl-Taql fragment of 
pGEM-Gas6 coding for N-terminal 50 residues of Gas6 was isolated 
and inserted into EcoRl-BamHl site of pBluescript with a synthetic 
EcoRV linker composed of 5'-CGGATATCG-3' and 5'-GATCCGA-
TATC-3'. The resulting plasmid (pBS-N) was cut with Clal and 
EcoRV and the insert was ligated into the C/aI/£coRV-digested 
pGEM-Gas6. To construct pGEM-ΔΕ and pGEM-AGE, pGEM-
Gas6 was digested with Clal, blunt-ended, and ligated with a Xhol 
linker. The resulting plasmid [pGEM(XhoI)-Gas6] was digested with 
Xhol and Ball and ligated with a synthetic linker composed of 
5'-TCGAGATATCGTGAGGACATCTTACCGTGTGTGCCCTTC-
AGCATGG-3' and 5'-CCATGCTGAAGGGCACACACGGTAA-
GATGTCCTCACGATATC-3'. The plasmid was then digested with 
Xhol and EcoRV, and ligated with a 400-bp Xhol-EcoRN fragment of 
pGEM(XhoI)-Gas6 to generate pGEM-ΔΕ, or was ligated with a 250-
bp XhoI-EcoRV fragment of pBS-N to generate pGEM-AGE. To 
construct pBS-AH-Myc, pBS-Gas6 was digested with Ball and Bam-
HI, blunt-ended, and ligated with a Xbal linker composed of 5'-
CCTCTAGA-3' and 5'-TCTAGAGG-3'. The resulting plasmid was 
digested with Xbal and SacII, and ligated with a synthetic XballSacll 
linker composed of 5'-CTAGTGAACAAAAGCTTATTTCTGAA-
GAAGACTTGTGAGCGGCCGCGAATTCCGC-3' and 5'-GGAA-
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TTCGCGGCCGCTCACAAGTCTTCTTCAGAAATAAGCTTTT-
GTTCA-3' (coding for a C-terminal Myc epitope peptide, SSEQKLI-
SEEDL) to generate pBS-AH-Myc. To construct plasmids for Myc-
tagged mutants (pGEM-Gas6-Myc, pGEM-AG-Myc, pGEM-AE-Myc 
and pGEM-AGE-Myc), a 820-bp Bfal fragment of pGEM-Gas6 was 
blunt-ended, and ligated with a Xbal linker. The resulting plasmid was 
digested with Sail and Xbal, and the 420-bp fragment was ligated into 
pBluescript with a XballSacll linker described above to generate pBS-
C-Myc. To generate pGEM-Gas6-Myc, pBS-C-Myc was digested with 
San and Notl and the insert was replaced with a SaWNotl fragment 
of pGEM-Gas6. pGEM-AG-Myc, pGEM-AE-Myc and pGEM-AGE-
Myc were generated, in a similar manner. The authenticity of 
the expression plasmids was confirmed by nucleotide sequence analy-
2.2. Preparation of recombinant Gas6 and its mutants 
The cDNA constructs were subcloned into the PUC-SRa expres-
sion vector [3], and the plasmids were transfected into COS-7 cells, 
using calcium phosphate methods. Cells were cultured for 3 days in 
serum-free Dulbecco's modified Eagle's medium (DMEM) with 2 μΜ 
vitamin K2 (Menatetrenone, Eisai, Tokyo). Gas6(-Gla), which was 
deficient in γ-carboxylation of Glu residues, was expressed in serum-
free DMEM in the presence of 1 μΜ Warfarin (a competitive inhib-
itor of vitamin K, Sigma) in place of vitamin K2. Recombinant Gas6 
was purified from conditioned medium, as described elsewhere [11]. 
Gas6(-Gla) was purified in a similar manner, except that its elution 
was monitored by dot-blot or Western blot analysis using an anti-
Gas6 antibody. The absence of Gla residues in Gas6(-Gla) was con-
firmed by amino acid analysis and amino acid sequencing [11]. As for 
Myc-tagged Gas6 mutants, except for ΔΗ-Myc, the conditioned media 
of COS cells were used after concentration with Centriprep-10 (Ami-
con). As ΔΗ-Myc was not secreted from the cells, the cell lysates were 
directly used for co-precipitation binding analyses. The concentrations 
of the purified Gas6 and Gas6(-Gla) were determined by amino acid 
analysis, and those of Myc-tagged mutants were densitometerically 
estimated based on immunoblots with 9E10 anti-Myc antibody (Santa 
Cruz Biotechnology), using Gas6-Myc as a standard. 
2.3. Binding assays 
Axl-Fc fusion proteins were expressed in COS-7 cells and purified 
as described previously [3,5]. Gas6 mutants were incubated at 4°C 
overnight with 5 nM Axl-Fc fusion protein and Protein A-Sepharose 
(30 μΐ of 50% slurry) in 200 μΐ of Hanks' balanced salt solution 
containing 20 mM Hepes (pH 7.0), 0.02% NaN3, and 1% bovine 
serum albumin. After centrifugation, the precipitates were washed 
4 times with cold phosphate-buffered saline (PBS), suspended in 
SDS sampling buffer, and subjected to SDS-PAGE. Bound proteins 
were detected by immunoblot analysis with anti-Gas6 antibody [3] or 
9E10 anti-Myc epitope antibody. BIAcore binding analysis was car-
ried out, as described previously [5]. Gas6 was passed over the immo-
bilized Axl-Fc fusion protein at a flow rate of 2 μΐ/min for 25 min. 
The dissociation constants (ΚΛ) were calculated, using the manufac-
turer's software (Pharmacia Biotech.). 
2.4. Tyrosine phosphorylation assay 
CHO cell lines (AM3) expressing Myc-tagged Axl (Axl-Myc) were 
constructed as described previously [5]. AM3 cells were cultured in 
Ham's F-12 medium supplemented with 10% fetal calf serum. The 
cells were serum-starved, treated with Gas6 mutants for 10 min at 
37°C, then rinsed 3 times with cold PBS containing 1 mM orthova-
nadate, followed by lysing with cold lysis buffer (20 mM Hepes (pH 
7.2), 1% Nonidet P-40, 10% glycerol, 50 mM NaF, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM orthovanadate, and 10 μ^piύ leupep-
tin). The lysates were immunoprecipitated with an anti-Myc antibody 
(9E10), run on SDS-PAGE, and immunoblotted with anti-phospho-
tyrosine monoclonal antibody (PY20, ICN Biomedicals), as described 
previously [3]. 
2.5. DNA synthesis 
NIH3T3 cells were maintained in DMEM supplemented with 10% 
fetal calf serum, and then serum-starved for 24 h in DMEM with 
0.1% BSA and 0.5 nM Axl-Fc. After the addition of 20 nM Gas6 
or its mutant, the cells were cultured for 14 h, then labeled with 10 
mM bromodeoxyuridine (BrdU) for 3 h. The BrdU incorporation was 
detected by a BrdU Detection Kit III (Boehringer Mannheim). 
Fig. 1. Requirement of vitamin K-dependent γ-carboxylation for receptor-binding and receptor-stimulating activities of Gas6. A (left): Immuno-
blot analysis of purified Gas6 and Gas6(-Gla), prepared in the presence and absence of vitamin K, respectively. A (right): Co-precipitation 
binding assay. Gas6 or Gas6(-Gla) (each 2 nM) was incubated with 5 nM Axl-Fc and Protein A-Sepharose. After centrifugation, the precipi-
tates were solubilized, run on SDS-PAGE and the bound Gas6 was visualized by immunoblot analysis with use of an anti-Gas6 antibody. Ar-
rows indicate the elution position of Gas6. Molecular sizes (kDa) of marker proteins are indicated on the left. B: BIAcore binding analyses. 
Each panel shows the sensorgram (RUs vs. time) for Gas6 or Gas6(-Gla) passed over the surface immobilized with Axl-Fc on a BIAcore in-
strument. The concentrations of Gas6 or Gas6(-Gla) injected are indicated. C: Axl tyrosine-phosphorylation activity. AM3 cells stably express-
ing Myc-tagged Axl (Axl-Myc) were treated for 10 min with 2 nM Gas6 or Gas6(-Gla). Cell lysates were immunoprecipitated with anti-Myc 
antibody, run on SDS-PAGE, and immunoblotted with anti-phosphotyrosine antibody (upper panel) or anti-Myc antibody (lower panel). Ar-
rows indicate the elution position of Axl-Myc. Molecular sizes (kDa) of marker proteins are indicated on the left. 
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3. Results 
3.1. Requirement of y-carboxylation for receptor-binding 
and -stimulating activities of Gas6 
To examine the role of vitamin K-dependent y-carboxyla-
tion for Gas6 activity, Gla-deficient Gas6 [Gas6(-Gla)] was 
prepared under vitamin K-depleted conditions. The absence 
of Gla residues was confirmed by amino acid analysis and 
amino acid sequencing [11]. The receptor-binding potential 
of Gas6(-Gla) was assessed by co-precipitation assay, using 
a chimeric soluble receptor (Axl-Fc) composed of the extra-
cellular ligand-binding domain of Axl fused to the Fc region 
of human immunoglobulin IgGl [5]. As shown in Fig. 1A, the 
binding ability to Axl-Fc was significantly decreased in Gas6-
(-Gla), when compared with Gas6 prepared in the presence of 
the vitamin K. Quantitative binding analyses using a BIAcore 
instrument revealed a significant decrease in the binding affin-
ity of Gas6(-Gla) to Axl-Fc and dissociation constants (K¿) of 
Gas6 and Gas6(-Gla) to Axl-Fc were calculated to be 0.4 nM 
and 4.1 nM, respectively (Fig. IB). 
As Gas6 was earlier shown to stimulate tyrosine-phospho-
rylation of Axl, Sky and Mer receptors [2-5], we examined the 
effect of γ-carboxylation of Gas6 on the activity to stimulate 
tyrosine-phosphorylation of Myc epitope-tagged Axl (Axl-
Myc) expressed on CHO cells. As shown in Fig. 1C, tyro-
sine-phosphorylation of Axl-Myc was induced by treatment 
with Gla-containing Gas6, but not with Gla-deficient Gas6-
(-Gla). Taken together these results suggest that vitamin In-
dependent γ-carboxylation is required for Gas6 to exhibit full 
activity to bind to and to stimulate Axl. 
3.2. An SHBG-like domain is sufficient for receptor-binding 
and -stimulating activities of Gas6 
To locate the functional domain(s) of Gas6 essential for its 
receptor-binding and biological activities, we constructed ex-
pression plasmids coding for a set of deletion mutants of 
Gas6, as shown in Fig. 2A. Each mutant was tagged with a 
Myc epitope peptide at the C-terminus, the objective being to 
detect and quantitate expression products with anti-Myc 
monoclonal antibody (9E10). Immunoblot analysis confirmed 
the expression of proteins of predicted molecular sizes (Fig. 
2B). Co-precipitation binding analyses revealed that Gas6-
Myc and its mutants, AG-Myc (deletion of the Gla domain), 
ΔΕ-Myc (deletion of four EGF-like domains) and AGE-Myc 
(deletion of Gla and four EGF-like domains), bound to Axl-
Fc, but ΔΗ-Myc (deletion of the C-terminal SHBG-like do-
main) did not (Fig. 2C). These observations, in accord with 
those of Mark et al. [19], indicate that the C-terminal SHBG-
like domain is necessary and sufficient for the receptor-bind-
ing activity of Gas6. 
To further define the role of an SHBG-like domain in Gas6 
activity, we examined if the AGE mutant composed of almost 
only the SHBG-like domain would stimulate tyrosine-phos-
Fig. 2. A: C-terminal SHBG-like domain is sufficient for receptor-
binding and receptor-stimulation activities of Gas6. A: Diagrams 
showing structures of rat Gas6 and variously deleted mutants used 
in this study. The hatched boxes represent Gla domains; black 
boxes, four EGF-like repeats; gray boxes, SHBG-like domains; and 
horizontally striped boxes, Myc-tag peptides. S, signal sequence. 
The numbers on top of the diagram of Gas6-Myc indicate amino 
acid residues flanking each domain and numbers on deleted mutants 
indicate the residues flanking deleted domains. B: Immunoblot anal-
yses of Gas6 mutant proteins. The serum-free conditioned media of 
COS cells transfected with plasmids coding for Gas6 mutants (ex-
cept for ΔΗ-Myc) were concentrated, run on SDS-PAGE, and im-
munoblotted with anti-Myc antibody. In the case of ΔΗ-Myc, cell 
lysates were used. C: Co-precipitation binding assay with Axl-Fc. 
Gas6 mutants (each 5 nM) were incubated with 5 nM Axl-Fc and 
Protein A-Sepharose. After centrifugation, the precipitates were 
solubilized, run on SDS-PAGE and the bound protein was visual-
ized by immunoblotting using an anti-Myc antibody. Molecular 
sizes (kDa) of marker proteins are indicated on the left. D: Axl ty-
rosine-phosphorylation activity of Gas6-Myc and AGE-Myc. CHO 
cells stably expressing Axl-Myc were treated for 10 min with 1-2 
nM of Gas6-Myc or AGE-Myc. Cell lysates were immunoprecipi-
tated with anti-Myc antibody, run on SDS-PAGE, and immuno-
blotted with anti-phosphotyrosine antibody (upper panel) or anti-
Myc antibody (lower panel). Arrows indicate the elution position of 
Axl-Myc. Molecular sizes (kDa) of marker proteins are indicated on 
the left. 
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not. AGE-Myc also stimulated the DNA synthesis of NIH3T3 
cells, with a potency similar to that of Gas6-Myc. These re-
sults suggest that γ-carboxylation of the Gla domain is re-
quired for the mitogenic activity of full-length Gas6, while 
only the C-terminal SHBG-like domain is sufficient for this 
activity. 
4. Discussion 
Fig. 3. Effects of Gas6 and its mutants on DNA synthesis of 
NIH3T3 cells. DNA synthesis was measured by BrdU incorpora-
tion, as described in Section 2. Each value represents the mean ± SE 
of triplicate measurements. 
phorylation of Axl receptor expressed on CHO cells. As 
shown in Fig. 2D, tyrosine-phosphorylation of Axl-Myc on 
AM3 cells was induced by AGE-Myc as well as Gas6-Myc, in 
a dose-dependent manner. AGE-Myc and Gas6-Myc also 
stimulated tyrosine-phosphorylation of Sky expressed on 
CHO cells (data not shown). 
3.3. Roles of y-carboxylation and an SHBG-like domain in 
mitogenic activity of Gas6 
We next examined the effects of Gas6 and Gas6 mutants on 
DNA synthesis of NIH3T3 cells. Gas6 was previously shown 
to be secreted from serum-starved NIH3T3 cells [1]. To ex-
clude the effect of endogenous Gas6, the cells were cultured in 
the presence of Axl-Fc during serum starvation, an approach 
which reduced the background level of BrdU incorporation. 
As shown in Fig. 3, Gas6 significantly stimulated the DNA 
synthesis of NIH3T3 cells, but Gla-deficient Gas6(-Gla) did 
We obtained evidence that γ-carboxylation of the Gla do-
main is required for receptor-binding and mitogenic activity 
of Gas6. We also showed that only the C-terminal SHBG-like 
domain of Gas6 has the potential to bind to Axl-Fc and to 
stimulate receptor tyrosine-phosphorylation and DNA synthe-
sis of fibroblasts. These results, together with recent report by 
Mark et al. [19], suggest that the C-terminal SHBG-like do-
main represents the entity essential for receptor-binding and 
biological activities of Gas6 while the N-terminal Gla domain 
plays a role to modulate the activity. It is presumed that the 
Gla-deficient (i.e. Glu) form of a Gla domain inhibits the 
receptor-binding and biological activities of Gas6 by intra-
(or inter-) molecularly interfering with receptor-binding func-
tions of the SHBG-like domain (Fig. 4). The γ-carboxylation 
of the Gla domain and subsequent Ca2+-binding to Gla res-
idues probably release this negative regulation. Ca2+-binding 
to Gla residues seems to be involved in this function of the 
Gla domain, since depletion of Ca2+ by treatment with EGTA 
or EDTA significantly reduced receptor-binding and stimulat-
ing activities of Gas6 [3,20]. Studies of Furie et al. on the Gla 
domain of the vitamin K-dependent blood clotting proteins 
indicated that two or three Gla residues bind a single Ca2+ to 
form a rigid conformation of the Gla domain, with intramo-
lecular bridges [16,21]. As shown in Fig. 4, such conforma-
tional changes mediated by Ca2+ may lead to exposure of a 
receptor-binding surface in the SHBG-like domain. In addi-
tion, as the Ca2+-bound Gla domain is thought to be involved 
in protein-membrane interactions through association with 
phospholipids [16,17], Gla residues in Gas6 may have a pro-
moting effect on ligand-receptor interactions on target cell 
membranes. Although vitamin K-dependent γ-carboxylation 
has been implicated in regulating blood coagulating systems, 
our evidence for requirement of γ-carboxylation for Gas6 ac-
tivity suggests that vitamin K also has a physiologically im-
Fig. 4. A model for regulation of Gas6 activity. In Gas6(-Gla), the Gla-deficient (Glu) form of a Gla domain negatively regulates the receptor-
binding and biological activities of Gas6 probably by masking the receptor-binding surface (indicated by a hatched area) within the SHBG-like 
domain. The vitamin K-dependent γ-carboxylation induces binding of Ca2+ and conformational changes, which lead to the 'active' conforma-
tion of Gas6 by exposing the receptor-binding surface of the SHBG-like domain. AGE mutant composed of almost only the SHBG-like domain 
retains receptor-binding and biological activities of Gas6. 
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portant role in the regulation of cell growth, survival and 
differentiation, through actions of Gas6. Each of four EGF-
like domains in Gas6 contains a consensus sequence for ß-
hydroxylation of Asp and Asn residues [22], the presence of 
which is correlated with a high-affinity Ca2+-binding site and 
seems to be involved in protein-protein interactions [23]. 
Thus, the EGF-like domains in Gas6 may play a role in sta-
bilizing an active conformation of Gas6 or modulating its 
activity. 
We reported that Gas6 binds to and stimulates Axl, Sky 
and Mer receptors [5]. The binding affinity of Mer to Gas6 
was relatively low, which means that Gas6-related protein(s) 
may function as preferable ligands for Mer. Identification of 
the C-terminal SHBG-like domain, as an essential domain for 
Gas6 activity, provides basic information needed for studies 
on Gas6-related proteins. 
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